COVID-19. U07.2 COVID-19, virus not identified, COVID-19
Conditions
Interventions
Intervention 1: Intervention group: The medicinal product includes a capsule composed of two herbs(salix ,lambs quarter). The amount of each of these substances in the capsule is 250 mg. The dosage of
Sponsors
Bagheiat-allah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Male or female patients 18 years old and older with COVID-19 positive coronavirus 19 PCR Ground glass view at low-dose CT scan Arterial oxygen saturation less than 93% Consciously completed consent form completed by the patient or the patient's supervisor
Exclusion criteria
Exclusion criteria: History of pulmonary malignancy History of asthma or COPD History of Disabling disease or malignancy Liver or kidney disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurement of cough severity. Timepoint: Day 1 before and at the end of treatment. Method of measurement: Standard cough questionnaire.;Severity of shortness of breath. Timepoint: Day 1 before and at the end of treatment. Method of measurement: Shortness Of Breath With Daily Activity (SOBDA) Questionnaire.;Lung radiologic changes. Timepoint: At beginning and end of the study. Method of measurement: Chest CT scan. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAhmad Reza Sharifi Olounabadi
Bagheiat-allah University of Medical Sciences
Outcome results
None listed